La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Roivant Sciences Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Roivant Sciences ha un patrimonio netto totale di $5.9B e un debito totale di $323.7M, che porta il suo rapporto debito/patrimonio netto a 5.5%. Le sue attività totali e le sue passività totali sono rispettivamente $6.5B e $601.2M.

Informazioni chiave

5.5%

Rapporto debito/patrimonio netto

US$323.72m

Debito

Indice di copertura degli interessi	n/a
Contanti	US$5.68b
Patrimonio netto	US$5.90b
Totale passività	US$601.16m
Totale attività	US$6.50b

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Roivant Sciences: Executing On Huge Buyback Program With More To Come

Jun 02

Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success

Mar 18

We Believe Roivant Sciences' (NASDAQ:ROIV) Earnings Are A Poor Guide For Its Profitability

Feb 21

These Analysts Just Made A Decent Downgrade To Their Roivant Sciences Ltd. (NASDAQ:ROIV) EPS Forecasts

Nov 15

Are Investors Undervaluing Roivant Sciences Ltd. (NASDAQ:ROIV) By 21%?

Apr 26

Broker Revenue Forecasts For Roivant Sciences Ltd. (NASDAQ:ROIV) Are Surging Higher

Nov 22

Newsflash: Roivant Sciences Ltd. (NASDAQ:ROIV) Analysts Have Been Trimming Their Revenue Forecasts

Sep 29

Roivant Sciences Ltd. (NASDAQ:ROIV) Analysts Are Reducing Their Forecasts For This Year

Aug 21

Roivant Sciences GAAP EPS of -$0.48, revenue of $4.32M

Aug 15

An Intrinsic Calculation For Roivant Sciences Ltd. (NASDAQ:ROIV) Suggests It's 22% Undervalued

Aug 12

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $6.0B ) di ROIV superano le sue passività a breve termine ( $215.0M ).

Passività a lungo termine: Le attività a breve termine di ROIV ( $6.0B ) superano le sue passività a lungo termine ( $386.1M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: ROIV ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di ROIV si è ridotto da 12.4% a 5.5% negli ultimi 5 anni.

Copertura del debito: Il flusso di cassa operativo di ROIV è negativo, pertanto il debito non è ben coperto.

Copertura degli interessi: Dati insufficienti per determinare se i pagamenti degli interessi sul debito di ROIV siano ben coperti dall'EBIT.

Roivant Sciences Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Consensus revenue estimates increase by 18%

New major risk - Earnings quality

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Roivant Sciences Ltd., Annual General Meeting, Sep 10, 2024

Roivant Sciences Ltd. to Report Q1, 2025 Results on Aug 08, 2024

Full year 2024 earnings: EPS in line with expectations, revenues disappoint

Roivant Sciences: Executing On Huge Buyback Program With More To Come

Consensus revenue estimates decrease by 17%, EPS upgraded

Now 20% undervalued

President exercised options and sold US$3.9m worth of stock

Roivant Sciences Ltd. (NasdaqGS:ROIV) announces an Equity Buyback for $1,500 million worth of its shares.

Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success

We Believe Roivant Sciences' (NASDAQ:ROIV) Earnings Are A Poor Guide For Its Profitability

Consensus EPS estimates increase by 7,400%

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

President & COO notifies of intention to sell stock

Roivant Sciences Ltd. to Report Q3, 2024 Results on Feb 13, 2024

Consensus EPS estimates increase from loss to US$0.07 profit

Forecast to breakeven in 2024

Insider recently sold US$33m worth of stock

High number of new directors

Roivant Sciences Ltd. and Priovant Therapeutics, Inc. Announces Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus

Roivant Sciences Ltd. and Priovant Therapeutics, Inc. Announces Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus

Consensus EPS estimates fall by 12%

These Analysts Just Made A Decent Downgrade To Their Roivant Sciences Ltd. (NASDAQ:ROIV) EPS Forecasts

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Roivant Appoints Mayukh Sukhatme to its Board of Directors

Roivant Sciences Ltd. to Report Q2, 2024 Results on Nov 13, 2023

President & COO notifies of intention to sell stock

President & COO notifies of intention to sell stock

Consensus revenue estimates fall by 11%

President & COO notifies of intention to sell stock

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Roivant Sciences Ltd. Announces the Resignation of Hiroshi Nomura from Board of Directors, Effective from August 31, 2023

Roivant Sciences Ltd. to Report Q1, 2024 Results on Aug 14, 2023

Roivant Sciences Ltd., Annual General Meeting, Sep 12, 2023

President & COO notifies of intention to sell stock

Roivant Sciences Reportedly Near Deal to Sell Stomach Drug to Roche for over $7 Billion

Consensus estimates of losses per share improve by 14%

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Roivant Sciences Ltd. to Report Q4, 2023 Results on Jun 28, 2023

Roivant Sciences Announces Positive Results from the Chronic Period of the Tuscany-2 Phase 2B Study of RVT-3101

Price target increased by 8.6% to US$14.78

President & COO notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Chief Accounting Officer notifies of intention to sell stock

Are Investors Undervaluing Roivant Sciences Ltd. (NASDAQ:ROIV) By 21%?

Now 20% undervalued

High number of new directors

CEO & Director notifies of intention to sell stock

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Roivant Sciences Ltd. has completed a Follow-on Equity Offering in the amount of $200 million.

Roivant Sciences Ltd. to Report Q3, 2023 Results on Feb 13, 2023

CEO & Director notifies of intention to sell stock

Price target increased to US$13.13

President & COO notifies of intention to sell stock

Price target increased to US$12.88

Roivant Sciences Ltd. Announces Positive Results from the Induction Period of the Tuscany-2 Phase 2B Study of RVT-3101

Price target increased to US$12.25

CEO & Director notifies of intention to sell stock

President & COO notifies of intention to sell stock

Roivant Sciences Ltd. Announces Resignation of Andrew Lo as Class II Director

Broker Revenue Forecasts For Roivant Sciences Ltd. (NASDAQ:ROIV) Are Surging Higher

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus forecasts updated

High number of new directors

Roivant Sciences Ltd. has completed a Follow-on Equity Offering in the amount of $150 million.

Roivant Sciences Ltd. has completed a Follow-on Equity Offering in the amount of $150 million.

CEO & Director notifies of intention to sell stock

Roivant Sciences Ltd. to Report Q2, 2023 Results on Nov 14, 2022

Consensus forecasts updated

Newsflash: Roivant Sciences Ltd. (NASDAQ:ROIV) Analysts Have Been Trimming Their Revenue Forecasts

CEO & Director notifies of intention to sell stock

Roivant Sciences Ltd. Announces Board Changes

Consensus revenue estimates increase by 14%